
TWST Stock Forecast & Price Target
TWST Analyst Ratings
Bulls say
Twist Bioscience is poised for potential growth and success with its unique silicon-based DNA synthesis platform and strong positioning in the growing field of AI-enabled drug discovery. The company has a proven track record of beating and raising quarterly estimates and is expected to continue this trend, with potential upside to FY26 revenue guidance. Its NGS segment is a core growth engine that is still underappreciated, while its margins are also expected to improve as the company moves towards profitability. Additionally, the company's focus on cost efficiency and capacity expansion position it well for future growth and profitability.
Bears say
Twist Bioscience is facing execution risk around margins and operating leverage due to its profitability story relying on continued gross margin improvement and disciplined expense control. The risks to the Medical and Life Science Tools sector also pose a challenge, as any reduction or delay in research and development budgets or government funding could impact Twist Bioscience's revenues. Additionally, while the company's recent financial results have been strong, there is a risk of a slowdown in its NGS momentum, potentially due to competition, customer concentration, or end-market variability.
This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.
TWST Analyst Forecast & Price Prediction
Start investing in TWST
Order type
Buy in
Order amount
Est. shares
0 shares